MONTREAL--(BUSINESS WIRE)--#CB1--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference. Details are as follows:
Conference Dates: Monday, May 2 and Tuesday, May 3, 2022
Location: Metro Toronto Convention Centre
30mn Presentation by Inversago: May 3 @ 4pm, Hall B
1-on-1 Meetings: Professional investors will have the opportunity to request 1-on-1 meetings with private and public companies, including Inversago Pharma. For information or registration, visit bloomburton.com/conference.
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.
About Inversago Pharma
Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Nephropathy (DN), Non-Alcoholic Steatohepatitis (NASH), complications from obesity, Hypertriglyceridemia (HTG), Type 1 Diabetes (T1D) and Prader-Willi Syndrome (PWS), as well as fibrotic indications like Progressive Fibrosis-Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF). For more information, visit inversago.com.
François Ravenelle, PhD
Chief Executive Officer
Inversago Pharma Inc.